Clinical trials: Diuresis
Cardiorenal Syndrome
Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)
The Cardiorenal Syndrome during Acute decompensated heart failure (ADHF) with persistent congestion despite high dose IV diuretic therapy is associated with remarkable morbidity, which can include the need for renal dialysis or…
- Trial name
- VOID-HF (NCT04227977)
- Testing
- JuxtaFlow System
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- 3ive Labs
Heart Failure
Monitoring Outpatient Blood VolumE in Heart Failure
In patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown.
- Trial name
- MOVE-HF (NCT04660396)
- Testing
- BVA-100
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Daxor Corporation
Heart Failure, Congestive
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are…
- Trial name
- NCT00159627
- Testing
- KW-3902IV
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Heart Failure, Congestive
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening…
- Trial name
- REACH UP (NCT00443690)
- Testing
- rolofylline
- Volunteers
- 480 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cardiac Surgery Associated - Acute Kidney Injury, AKI - Acute Kidney Injury
Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury
The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated…
- Trial name
- SAFEGUARD (NCT07123935)
- Testing
- RenalGuard® Therapy, Standard of Care (SOC)
- Where
- 2 sites in Malaysia
- Volunteers
- 300 people
- Sponsor
- CardioRenal Systems, Inc.
Congestive Heart Failure, Renal Impairment
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
- Trial name
- NCT00652782
- Testing
- rolofyline
- Volunteers
- 160 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bioequivalence Study in Healthy Subjects, PK/PD
Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects
This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone).
- Trial name
- NCT07015671
- Testing
- 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Congestive Heart Failure
Reprieve ADHF EFS IDE
This is a prospective, single arm, early feasibility study (EFS) designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart…
- Trial name
- NCT03866551
- Testing
- Reprieve Cardiovascular System
- Volunteers
- 40 people
- Sponsor
- CardioRenal Systems, Inc.
Heart Failure
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure
- Trial name
- NCT02914665
- Testing
- elamipretide
- Where
- 46 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 308 people
- Sponsor
- Stealth BioTherapeutics Inc.